Darren Kelly, Certa Therapeutics CEO
February 7, 2023 10:59 AM EST
R&D

Aus­tralian biotech touts a pos­i­tive mid-stage da­ta read­out — with old Shire drug

Paul Schloesser

Associate Editor

A qui­et biotech is re­port­ing some pos­i­tive da­ta in a rare fi­brot­ic dis­ease.
Cer­ta Ther­a­peu­tics — based in Mel­bourne, Aus­tralia — re­port­ed Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times